From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 1-7

  Steinman, Lawrence ^a   Shoenfeld, Yehuda ^b  

^a STANFORD UNIVERSITY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antigenicity; Experimental allergic encephalomyelitis; Inflammation; Multiple sclerosis

Indexed keywords

ANTIGEN; FINGOLIMOD; GLATIRAMER; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANTIBIOTIC RESISTANCE; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PARABIOSIS; PARALYSIS; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DIET THERAPY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HISTORY; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FINGOLIMOD HYDROCHLORIDE; GLATIRAMER ACETATE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NATALIZUMAB; PEPTIDES; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84908375090     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.08.001     Document Type: Review

References (72)

1. Teitelbaum D., Meshorer M., Hirshfeld T., Sela M., Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971, 1:242-248.
2. McDevitt H.O., Sela M. Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. JExp Med 1965, 122(3):517-531.
3. McDevitt H.O., Tyan M.L. Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus. JExp Med 1968, 128(1):1-11.
4. Arnon R., Sela M. Immunomodulation by the copolymer glatiramer acetate. JMol Recognit 2003, 16:412-421.
5. Teitelbaum D., Webb C., Meshorer A., Arnon A., Sela M. Protection against experimental allergic encephalomyelitis. Nature 1972, 240:564-566.
6. Shaw C.M., Fahlenberg W.J., Kies M.W., Alvord E.C. Suppression of experimental "allergic" encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain. JExp Med 1960, 111:171-180.
7. Rivers T.M., Sprunt D.H., Berry G.P. Observations on attempts to induce experimental encephalomyelitis in monkeys. JExp Med 1933, 58(1):39-53.
8. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurology 2006, 60:12-21.
9. Lederberg J., Lederberg E.M. Replica plating and indirect selection of bacterial mutants. JBacteriol 1952, 63:399-406.
10. http://www.laskerfoundation.org/awards/2010_b_description.htm.
11. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, etal. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.New Engl J Med 317(7): 408-414.
12. Stamper H.B., Woodruff J.J. Lymphocyte homing into lymph nodes: invitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. JExp Med 1976, 144:828-833. http://dx.doi.org/10.1084/jem.144.3.828.
13. Gallatin W.M., Weissman I.L., Butcher E.C. Acell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983, 304:30-34. http://dx.doi.org/10.1038/304030a0.
14. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. JCell Biology 2012, 199(3):413-416.
15. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66. http://dx.doi.org/10.1038/356063a0.
16. U.S.Food and Drug Administration Public health advisory: suspended marketing of tysabri (natalizumab) 2005, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInfo%20rmationforHeathcareProfessionals/PublicHealthAdvisories/ucm051761.htm.
17. Gorelik L., Lerner M., Bixler S., Crossman M., Schlain B., Simon K., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303.
18. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEngl J Med 2012, 366:1870-1880.
19. Tysabri (natalizumab) Benefit/Risk Update & PML Stratification. February 2014. Biogen Idec Inc. Available at: [accessed on 11.3.14]. http://www.slideshare.net/gavingiovannoni/tysabri-benefit-risk-update-february-2014.
20. Karin N., Mitchell D., Ling N., Brocke S., Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of Interferon-_ and TNF-a production. JExp Med 1994, 180:2227-2237.
21. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379:343-345.
22. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P. Steinman L and the APL in relapsing ms study group. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat Med 2000, 6(10):1176-1182.
23. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 Oct, 6(10):1167-1175.
24. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E., et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001, 2:216-222.
25. Genain C.P., Zamvil S.S. Specific immunotherapy: one size does not fit all. Nat Med 2000 Oct, 6(10):1098-1100.
26. Ray A., Basu S. Regulatory B cells in experimental autoimmune encephalomyelitis (EAE). Methods Mol Biol 2014, 1190:243-255.
27. Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol, [in press].
28. Thiruppathi M., Sheng J.R., Li L., Prabhakar B.S., Meriggioli M.N. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun 2014, 52:64-73.
29. Mayer C.T., Huntenburg J., Nandan A., Schmitt E., Czeloth N., Sparwasser T. CD4 blockade directly inhibits mouse and human CD4(+) T cell functions independent of Foxp3(+) Tregs. JAutoimmun 2013, 47:73-82.
30. Roncarolo M.G., Gregori S., Bacchetta R., Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol 2014, 380:39-68.
31. Ellis SD, McGovern JL, van Maurik A, Howe D, Ehrenstein MR, and Notley CA. Induced CD8+FOXP3+ regulatory T cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane TNF-α and CD86. Arthritis Rheumatol, [in press].
32. Suzuki E., Mellins E.D., Gershwin M.E., Nestle F.O., Adamopoulos I.E. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014, 13(4-5):496-502.
33. Kessel A., Vadasz Z., Toubi E. Cogan syndrome-pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2014, 13(4-5):351-354.
34. Fissolo N, Montalban X, and Comabella M. DNA vaccination techniques. Methods Mol Biol, [in press].
35. Yang X., Zheng S.G. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev 2014, 13(6):615-620.
36. Walker L.S. Treg and CTLA-4: two intertwining pathways to immune tolerance. JAutoimmun 2013, 45:49-57.
37. Gravano D.M., Hoyer K.K. Promotion and prevention of autoimmune disease by CD8+ T cells. JAutoimmun 2013, 45:68-79.
38. Kissick H.T., Sanda M.G., Dunn L.K., Pellegrini K.L., On S.T., Noel J.K. Arredouani MS. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci USA 2014, 111(27):9887-9892.
39. Boettler T., Pagni P.P., Jaffe R., Cheng Y., Zerhouni P., von Herrath M. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. JAutoimmun 2013, 44:40-48.
40. Markakis I, Alexopoulos H, Poulopoulou C, Akrivou S, Papathanasiou A, Katsiva V, etal. Immunotherapy-responsive limbic encephalitits with antibodies to glutamic acid decarboxylase. J Neurol Sci, [in press].
41. Robinson A.P., Caldis M.W., Harp C.T., Goings G.E., Miller S.D. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. JAutoimmun 2013, 43:32-43.
42. Wen J., Xia Y., Stock A., Michaelson J.S., Burkly L.C., Gulinello M., et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. JAutoimmun 2013, 43:44-54.
43. Ben-Ami E., Miller A., Berrih-Aknin S. Tcells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2. Autoimmun Rev 2014, 13(2):187-196.
44. Vudattu N.K., Waldron-Lynch F., Truman L.A., Deng S., Preston-Hurlburt P., Torres R., et al. Humanized mice as a model for aberrant responses in human T cell immunotherapy. JImmunol 2014, 193(2):587-596.
45. Geuking MB, Koller Y, Rupp S, and McCoy KD. The interplay between the gut microbiota and the immune system. Gut Microbes, 5(3), [in press].
46. Priya Doss C.G., Agoramoorthy G., Chakraborty C. TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases. Front Biosci Landmark Ed 2014, 19:1028-1040.
47. Liberal R., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: a comprehensive review. JAutoimmun 2013, 41:126-139.
48. Koristka S., Cartellieri M., Arndt C., Bippes C.C., Feldmann A., Michalk I., et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. JAutoimmun 2013, 42:105-116.
49. Smilek D.E., Ehlers M.R., Nepom G.T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 2014, 7(5):503-513.
50. Samavedam U.K., Kalies K., Scheller J., Sadeghi H., Gupta Y., Jonkman M.F., et al. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. JAutoimmun 2013, 40:74-85.
51. Abisror N., Mekinian A., Lavigne C., Vandenhende M.A., Soussan M., Fain O. Club rhumatismes et inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013, 12(12):1143-1149.
52. Berman H., Rodriguez-Pinto I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. Catastrophic antiphospholipid syndrome (CAPS) registry project group (European Forum on antiphospholipid antibodies). Autoimmun Rev 2013, 12(11):1085-1090.
53. Blink S.E., Caldis M.W., Goings G.E., Harp C.T., Malissen B., Prinz I., et al. γδ T cell subsets play opposing roles in regulating experimental autoimmune encephalomyelitis. Cell Immunol 2014, 290(1):39-51.
54. Liang Y, Pan HF, and Ye DQ. Therapeutic potential of STAT4 in autoimmunity. Expert Opin Ther Targets, 1-16, [in press].
55. Pollard K.M., Hultman P., Toomey C.B., Cauvi D.M., Hoffman H.M., Hamel J.C., et al. Definition of IFN-γ-related pathways critical for chemically-induced systemic autoimmunity. JAutoimmun 2012, 39(4):323-331.
56. Prasad S., Kohm A.P., McMahon J.S., Luo X., Miller S.D. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. JAutoimmun 2012, 39(4):347-353.
57. Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014, 13(1):15-19.
58. Othy S., Bruneval P., Topcu S., Dugail I., Delers F., Lacroix-Desmazes S., et al. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation. JAutoimmun 2012, 39(3):168-172.
59. Isono F, Fujita-Sato S, and Ito S. Inhibiting RORγt/Th17 axis for autoimmune disorders. Drug Discov Today, [in press].
60. Abdulahad W.H., Kroese F.G., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. JAutoimmun 2012, 39(1-2):103-111.
61. Sammicheli S., Ruffin N., Lantto R., Vivar N., Chiodi F., Rethi B. IL-7 modulates B cells survival and activation by inducing BAFF and CD70 expression in T cells. JAutoimmun 2012, 38(4):304-314.
62. Breuer J., Schwab N., Schneider-Hohendorf T., Marziniak M., Mohan H., Bhatia U., et al. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol 2014, 75(5):739-758.
63. Everds N.E., Tarrant J.M. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013, 41(2):280-302.
64. Luijten R.K., Fritsch-Stork R.D., Bijlsma J.W., Derksen R.H. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013, 12(5):617-628.
65. Zhang J., Huang Z., Sun R., Tian Z., Wei H. IFN-γ induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice. JAutoimmun 2012, 38(1):20-28.
66. Yan Y., Wang Y.H., Diamond B. IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells. JAutoimmun 2012, 38(1):1-9.
67. Muller J., Nitschke L. The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol 2014, 10(7):422-428.
68. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. JAutoimmun 2013, 45:97-103.
69. Robinson W.H., Fontoura P., Lee B.J., Neuman de Vegvar H.E., Tom J., Pedotti R., et al. Reverse genomics: protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003, 21:1033-1039.
70. Garren H., Robinson W., Krasulová E., Havrdová E., Nadj C., Selmaj K., et al. Steinman l and the BHT-3009 study group. Phase 2b trial of a DNA vaccine Encoding myelin basic protein in relapsing multiple sclerosis. Ann Neurology 2008, 63(5):611-620.
71. Roep B.O., Solvason N., Gottlieb P.A., Abreu J.R.F., Harrison L.C., Eisenbarth G.S., et al. Plasmid encoded proinsulin preserves C-peptide while specifically reducing proinsulin specific CD8 T cells in type 1 diabetes. Sci Transl Med 2013, 5(191). 191ra82. 10.1126/scitranslmed.3006103.
72. Kurnellas M.P., Adams C.M., Sobel R.A., Steinman L., Rothbard J.R. Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med 2013, 5(179). 179ra42.